Allergan roasts fad fat-fighting techniques in new 'Not Cool vs. Cool' campaign

Ian Poulter
Allergan has brought on golfer Ian Poulter to talk up its CoolSculpting technology, a fat-fighting product it hopes can bring in new male customers. (Keith Allison/CC BY-SA 2.0)

Those over-the-top, fad techniques for tackling stubborn body fat? Not cool, Allergan says. And it’s got an alternative.

The company recently rolled out “Not Cool vs. Cool,” a multichannel campaign promoting the CoolSculpting system it added last year with its $2.47 billion buyout of Zeltiq. In a new spot, the company spoofs fat-fighting methods with the “roasted core wrap,” in which a woman wraps her midsection in plastic film in preparation for zapping with red lamps.

RELATED: Can Allergan's spruced-up aesthetics lineup shake off 'meh' Kybella growth?

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

With the new campaign, Allergan has also added to its long list of celebrity partners, signing athletes the company says are known for their “cool” on the ice and on the green. Figure skater Johnny Weir and golfer Ian Poulter, both of whom have had CoolSculpting treatments, have joined the effort; Allergan’s hope is that they’ll help the company reach men, a population it consistently lists as a key aesthetics growth area

“Of the 35 million consumers expressing interest in CoolSculpting, more than 46% are male,” Michael Jafar, Allergan’s VP of body contouring, said in a statement, adding that CoolSculpting has “a unique opportunity with male consumers.”

CoolSculpting has so far come up big for Allergan, exceeding the company’s U.S. expectations, commercial chief Bill Meury has said. And that’s a good thing for the company, because fellow fat-fighter Kybella has struggled to gain traction.

RELATED: Where could Allergan’s cost cuts fall? DTC spending, for starters

The product’s early success is also the reason it’s seeing new DTC investment at a time when the company is cutting back on advertising costs in other parts of its portfolio. For some of the company’s businesses, “the investment level’s got to be moderated,” Meury said on Allergan’s third-quarter conference call.


Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.